Baseline cytopenias and hematotoxicity after CAR T-cell therapy in B-ALL. (A-B) Baseline ANCs and platelet counts were plotted for all patients in the NCI B-ALL cohort. Median and 95% confidence intervals are shown with black lines. (C) Cumulative days of neutropenia (ANC <500/μL between CAR T-cell infusion [D0] and day+30 [D30] post-CAR T-cell infusion) were plotted for all patients in the NCI B-ALL cohort. Median and 95% confidence intervals are shown. (D) Proportion of patients with severe prolonged neutropenia (ANC <500/μL for ≥14 days between D0 and D30 post-CAR T-cell infusion) compared with no severe prolonged neutropenia. (E) Proportion of patients with grade (Gr) 3 or 4 neutropenia (ANC <1000/μL) or thrombocytopenia (platelet count <50 × 10³/μL) at D30. (F) Proportion of patients who had neutrophil recovery (ANC >500/μL for 3 consecutive days) at D30. (G) Proportion of patients who had platelet count recovery (platelet count >50 × 10³/μL for 3 consecutive days) at D30. (H) Proportion of patients who had ANC and platelet count recovery, ANC recovery only, platelet count recovery only, or no ANC or platelet count recovery at D30. (I) Early ICAHT grading distribution.